In direct-compression oral tablet manufacture, L-glutathione imposes two immediate process constraints: a small particle size distribution with poor flow and a free thiol group that oxidizes in the presence of moisture and trace transition metals. The API is therefore handled in a humidity-controlled suite with room air held at 20–25 °C and RH ≤40%, and aqueous cleaning of equipment is replaced by dry wiping with sanitized lint-free wipes to prevent localized water uptake. Blends containing 25–50 wt% API are prepared by geometric mixing with spray-dried mannitol, microcrystalline cellulose Avicel PH-102, croscarmellose sodium at 2.0 wt%, and colloidal silicon dioxide at 0.5 wt%. The blend is passed through a 0.8 mm sieve and transferred to a rotary tablet press equipped with a paddle feeder rotating at 15–25 rpm; this equipment configuration reduces segregation of needle-like API crystals across the die table. Tablet mass is maintained at 400–600 mg depending on label claim, and press speed is set between 20 and 40 rpm for a 10-station tooling set. Hardness is controlled between 60 and 90 N, and friability is kept below 1.0% per USP <1216>. Weight variation is evaluated against USP <905>, disintegration against USP <701> in water at 37±2 °C, and dissolution against USP <711> using 900 mL of water and paddle speed 50 rpm. Direct compression above 50 wt% API is not recommended because the blend flow function coefficient measured by ASTM D6773-21 falls below the free-flow threshold, producing die fill variability and capping.

Why Does L-Glutathione Require Low-Humidity Processing in Gelatin and HPMC Capsule Filling?

Hard-shell capsule filling introduces a moisture exchange interface that is not present in uncoated tablets. At 45–55% RH, gelatin shells contain 13–15% w/w water, while HPMC shells at the same ambient condition contain 2–5% w/w water; the gradient from shell to powder bed is sufficient to raise the free moisture of a hygroscopic L-glutathione granule above its stability threshold. Capsule fills are therefore prepared by dry granulation—slugging on a rotary press at 8–12 kN force followed by oscillating granulator sieve 1.0 mm—or by roller compaction with roll force 5–8 kN/cm and screen size 0.8–1.2 mm. The resulting granules are filled on a tamping-pin capsule machine with dosing disc thickness selected to deliver ±5% weight variation; filling room conditions are held at 25–30% RH and 21–24 °C. Lubrication with magnesium stearate is restricted to 0.25–0.5 wt% because high-shear blending above 5 min and concentrations above 1.0 wt% have been associated with delayed dissolution of the tripeptide in capsule powder plugs. The filled capsules are inspected for shell brittleness caused by excessive moisture removal, particularly in gelatin shells below 10% w/w shell water, and then packed in HDPE bottles with a 1 g silica gel desiccant canister. Release testing includes moisture by USP <921> with a limit of ≤2.0% w/w, dissolution by USP <711> in 900 mL water at 50 rpm, and assay of the reduced form with simultaneous quantification of oxidized glutathione impurity using an HPLC method capable of resolving the oxidized dimer from the free thiol.

Wet Granulation Limits for Effervescent Oral Granule Dosage Forms

Effervescent oral granules require a granulation process in which the vehicle is anhydrous ethanol or isopropanol; any granulating water initiates the acid-carbonate reaction in the granulator and generates carbon dioxide before the product reaches the stick pack. The wet mass is prepared from anhydrous citric acid, sodium bicarbonate, L-glutathione, sucrose or sorbitol, and polyvinylpyrrolidone K30 at 2–4 wt% as binder. The solvent is sprayed into a high-shear granulator at 8–12% w/w of dry powder mass, with impeller speed 150–250 rpm and chopper speed 1000–1500 rpm for 3–5 min. The wet granules are dried in a fluid-bed dryer with inlet air temperature 40–50 °C and product temperature held below 35 °C; final moisture is controlled at ≤0.8% w/w by USP <921>. The dried granule is milled to a target fraction of 200–1000 μm, as measured by sieve analysis according to Ph. Eur. 2.9.12. Fill weight per stick pack is maintained at 2–5 g, and the packet is sealed with a desiccant-compatible laminate to prevent ingress of water vapor. During quality control, effervescent dispersion is monitored by the time required for the granule mass to disperse in 200 mL water at 20±2 °C; the maximum target is 3 min, beyond which residual acid pockets or undispersed API clusters trigger batch rejection. A process risk specific to L-glutathione in this dosage form is the acidic microenvironment created by dissolved citric acid; although reduced glutathione is more stable in acid than at neutral pH, the presence of dissolved oxygen and trace iron from the sodium bicarbonate can still generate the oxidized dimer. The bicarbonate source is therefore specified with heavy-metal limits according to Ph. Eur. 2.4.8 or a validated ICP-MS limit for iron, copper, and chromium, and the production area is purged with nitrogen where enclosed transfer is used.

Aseptic lyophilization of L-glutathione for injectable vials begins with dissolution in Water for Injection at 5–15 °C under filtered nitrogen, because oxygen solubility increases as water temperature decreases and the free thiol is oxidized by dissolved oxygen in neutral-to-alkaline solution. Mannitol is added as a bulking agent at 2–5% w/v, and the pH is not adjusted upward unless necessary because oxidation of the thiol accelerates above pH 6.5; if pH adjustment is required, sterile-filtered 1 N sodium hydroxide is used dropwise with continuous pH measurement to avoid local alkaline zones. The bulk solution is pre-filtered through a 0.45 µm filter and then sterile-filtered through a 0.22 µm membrane with an integrity test performed before and after filling according to ASTM F838-20. Filling is performed in an isolator or RABS with nitrogen overlays to keep headspace oxygen below 2% v/v. The filled vials are partially stoppered with chlorobutyl rubber closures and loaded into a freeze-dryer with shelf temperature controlled at -45 °C for at least 2 h after the product reaches -35 °C. Primary drying is conducted at chamber pressure 80–150 mTorr and shelf temperature -20 to -10 °C, with endpoint determined by comparative Pirani and capacitance manometer readings; secondary drying is ramped to 25–30 °C over 3–5 h and held until residual moisture is ≤3.0% w/w by USP <921>. Overdrying below 1.0% w/w is not automatically beneficial because brittle cakes may fracture and lengthen reconstitution time; the reconstitution specification in Water for Injection is usually ≤60 s at manual swirling speed. Finished vials are tested for sterility by USP <71>, bacterial endotoxin by USP <85>, particulate matter by USP <788>, and container closure integrity by USP <1207>. Because a 600 mg dose reconstituted in 4 mL Water for Injection can produce an osmolarity above physiological range, osmolality is measured by USP <785> and the product is diluted into 0.9% sodium chloride or 5% dextrose before intravenous infusion unless a specific hypertonic bolus is intended. The principal operational boundary is exclusion of terminal steam sterilization at 121 °C because the thermal cycle raises the oxidized dimer impurity above the established specification and may darken the lyophilized cake.

When Terminal Sterilization Is Replaced by Aseptic Filtration in Glutathione Injection

Ready-to-use injectable solutions of L-glutathione differ from lyophilized vials in one critical respect: the API remains in aqueous contact from the moment of compounding until administration, so the oxidation state of the free thiol controls the entire shelf life. Terminal sterilization by steam at 121 °C for 15 min is excluded on product-stability grounds; the validated process is therefore aseptic filtration through a 0.22 µm membrane into depyrogenated Type I glass vials under nitrogen. The bulk solution is prepared in a closed vessel with a nitrogen sparge line and a dissolved oxygen probe; the target dissolved oxygen is <0.5 mg/L before filtration, and the filling line is equipped with a residual oxygen monitor to maintain headspace oxygen below 2% v/v. The solution pH is held between 5.0 and 6.0, and disodium edetate is added at 0.02–0.05% w/v to chelate trace iron and copper leached from stainless steel fittings, because metal ion catalysis is faster than auto-oxidation for thiol compounds. Amber glass vials are used as an outer light barrier; the closure is a siliconized chlorobutyl stopper with low water-vapor transmission. In-process filter integrity testing follows ASTM F838-20, and the release panel includes particulate matter USP <788>, sterility USP <71>, endotoxin USP <85>, pH USP <791>, and an HPLC method that quantifies reduced glutathione and the oxidized dimer. The elemental impurity risk assessment follows ICH Q3D with emphasis on copper, iron, and chromium. The operational boundary is that no oxidizable headspace greater than 2% v/v oxygen should remain in the vial; if the filling line cannot consistently achieve this target, the alternative is nitrogen-flushed ampoules with a smaller headspace volume rather than relaxing the limit. Solutions containing visible yellowing or an oxidized dimer content above the specification are rejected, and the batch record must document the time interval between bulk solution preparation and final filter use because solution hold time is a stability-critical process parameter.

Combination Oral Solids with Ascorbic Acid and Alpha-Lipoic Acid

Fixed-dose oral combinations of L-glutathione with ascorbic acid and alpha-lipoic acid introduce an acidic microclimate and competing antioxidant redox behavior within a single dosage unit. Ascorbic acid maintains glutathione in its reduced form in solution, but its solid-state contact with L-glutathione can lower the local pH and absorb moisture, producing a tacky granule surface and measurable oxidation during accelerated stability. A bilayer tablet or a two-compartment hard capsule is therefore used instead of a single homogeneous blend. The L-glutathione layer is dry-granulated with mannitol and croscarmellose sodium; the ascorbic acid layer is wet-granulated separately with anhydrous ethanol and later combined on a bilayer press with a main compression force of 10–15 kN and a pre-compression force of 1.5–2.5 kN. Alpha-lipoic acid is placed in the same layer as ascorbic acid only if physical contact has been confirmed to avoid melt-mediated degradation; alpha-lipoic acid has a low melting range near 58–62 °C, and heated drying of this layer is avoided. Dissolution testing uses USP <711> apparatus II with 900 mL of 0.1 N hydrochloric acid or water at paddle speed 75 rpm, and the assay must separately quantify reduced glutathione, ascorbic acid, and alpha-lipoic acid by a stability-indicating HPLC method. Published stability data for this specific fixed-dose configuration are limited; therefore, compatibility studies under ICH Q1A(R2) conditions are required before a manufacturer can assign a shelf life.